PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23464532-0	2013	Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin.	AZD1656	50-57	glucokinase	Homo sapiens	28-39	
23522182-0	2013	Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus.	AZD1656	50-57	glucokinase	Homo sapiens	28-39	
23522182-1	2013	AIM: To assess the glucose-lowering effects of monotherapy with the glucokinase activator AZD1656 in Japanese patients with type 2 diabetes mellitus.	AZD1656	90-97	glucokinase	Homo sapiens	68-79	
23464532-1	2013	AIM: To investigate the effect of glucokinase activator AZD1656 on glycated haemoglobin (HbA1c) as an add-on to metformin in patients with type 2 diabetes.	AZD1656	56-63	glucokinase	Homo sapiens	34-45	
34853102-4	2021	The specific glucokinase activator AZD1656 may address both of these challenges via its glucose-lowering effect and its immunological mechanism of action.	AZD1656	35-42	glucokinase	Homo sapiens	13-24	
22943931-0	2012	Tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator AZD1656, after single ascending doses in healthy subjects during euglycemic clamp.	AZD1656	82-89	glucokinase	Homo sapiens	60-71	
22943931-1	2012	OBJECTIVES: AZD1656 is a novel glucokinase activator with a postulated dual mechanism of action by activating glucokinase in both the pancreas and the liver, and with the potential to deliver effective glucose-lowering in Type 2 diabetes mellitus.	AZD1656	12-19	glucokinase	Homo sapiens	31-42	
22943931-1	2012	OBJECTIVES: AZD1656 is a novel glucokinase activator with a postulated dual mechanism of action by activating glucokinase in both the pancreas and the liver, and with the potential to deliver effective glucose-lowering in Type 2 diabetes mellitus.	AZD1656	12-19	glucokinase	Homo sapiens	110-121